Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | ATP4A | P20648 | 1/20 | 0.31 |
| ▸ | ATP4B | P51164 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CBFB | Q13951 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10617685 | 0.91 | CBFB (0.40) | KIF11CBFBMETAP2METAP1CYP1A2 | |
| SCHEMBL10616882 | 0.89 | CXCR4 (0.33) | TRPV1TRPC5KIF11CXCR4ATP4A | |
| SCHEMBL10616910 | 0.88 | METAP2 (0.38) | TRPV1CBFBKDM4EMEN1USP2 | |
| SCHEMBL6880554 | 0.87 | TRPV1 (0.37) | TRPV1KCNH2CBFBKDM4EALDH1A1 | |
| SCHEMBL6878662 | 0.86 | CXCR4 (0.41) | CXCR4KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL6461676 | 0.84 | METAP2 (0.40) | TRPV1CXCR4MEN1GAAKMT2A | |
| SCHEMBL10617520 | 0.84 | CBFB (0.40) | KIF11KCNH2CBFBMAPTKMT2A | |
| SCHEMBL10616921 | 0.81 | CBFB (0.48) | CBFBKDM4EUSP2ALDH1A1GAA | |
| SCHEMBL10617004 | 0.80 | CBFB (0.47) | TRPV1KCNH2CBFBKDM4EMEN1 | |
| SCHEMBL10616888 | 0.80 | CBFB (0.40) | KIF11CXCR4CBFBALDH1A1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | claimed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | claimed |
| EP-0045200-A1 | Benzimidazoles and their pharmaceutical use | THE UPJOHN COMPANY (US) | 1982-02-03 | — | — | EP | claimed |
| US-4045563-A | Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects | AB HASSLE (SW) | 1977-08-30 | — | — | US | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| EP-0045200-B1 | BENZIMIDAZOLES AND THEIR PHARMACEUTICAL USE | THE UPJOHN COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4359465-A | HETEROCYCLIC ALKYLSULFINYL BENZIMIDAZOLES | THE UPJOHN COMPANY (US) | 1982-11-16 | — | — | US | disclosed |
| EP-0045200-A1 | Benzimidazoles and their pharmaceutical use | THE UPJOHN COMPANY (US) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | TRPV1 1145/4885TRPC5 3387/4885KIF11 3545/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | TRPV1 351/4885TRPC5 2015/4885KIF11 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.